Kyowa Hakko Kirin Co. Ltd. – Asian Scientist Magazine

kyowa hakko kirin co ltd

GHIT Announces Ten New Funding Partnerships

The Global Health Innovative Technology Fund has ten new funding partners that include major global pharmaceutical and biotechnology companies.

Pharma

Kyowa Hakko Kirin & Syndax To Develop Tumor Therapy

Entinostat, an epigenetic modification drug, is slated for clinical trials in Japan and Korea in 2015.

Pharma

Bristol-Myers Squibb, Kyowa Hakko Kirin To Commercialize Coniel In China

Bristol-Myers Squibb and Kyowa Hakko Kirin will commercialize Coniel, a calcium channel blocker for the treatment of hypertension and angina pectoris, in China.

Pharma

Kyowa Kirin Starts Phase III Trial Of ARQ197/Erlotinib In NSC Lung Cancer

Kyowa Hakko Kirin is starting a Phase III trial evaluating the combination of ARQ 197 (tivantinib) and erlotinib in Asia for patients with advanced or metastatic non-small cell lung cancer.

EDITOR’S PICK

10 Years Of Celebrating Asia’s Researchers

Every year, Asian Scientist Magazine publishes Asian Scientist 100, a carefully curated list of the best and brightest researchers and leaders in SETM in Asia. This year we complete a decade of doing so.
Learning From Environmental Defenders

Drawing on traditional knowledge systems, environmental researchers and policymakers in Asia are working with indigenous communities to design better strategies for environmental conservation.
The Equalizers

Across Asia, people with disabilities are breaking physical and social barriers to STEM fields, opening the way for others.

GHIT Announces Ten New Funding Partnerships

Kyowa Hakko Kirin & Syndax To Develop Tumor Therapy

Bristol-Myers Squibb, Kyowa Hakko Kirin To Commercialize Coniel In China

Kyowa Kirin Starts Phase III Trial Of ARQ197/Erlotinib In NSC Lung Cancer

EDITOR’S PICK

10 Years Of Celebrating Asia’s Researchers

Learning From Environmental Defenders

The Equalizers